Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
23.24
-1.21 (-4.95%)
At close: Oct 2, 2026, 4:00 PM EDT
23.00
-0.24 (-1.02%)
After-hours: Oct 2, 2026, 7:44 PM EDT
Tango Therapeutics Employees
Tango Therapeutics had 137 employees as of December 31, 2025. The number of employees decreased by 18 or -11.61% compared to the previous year.
Employees
137
Change (1Y)
-18
Growth (1Y)
-11.61%
Revenue / Employee
$392,781
Profits / Employee
-$903,073
Market Cap
3.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 137 | -18 | -11.61% |
| Dec 31, 2024 | 155 | 15 | 10.71% |
| Dec 31, 2023 | 140 | 30 | 27.27% |
| Dec 31, 2022 | 110 | 19 | 20.88% |
| Sep 30, 2022 | 109 | 26 | 31.33% |
| Jun 30, 2022 | 103 | 17 | 19.77% |
| Mar 31, 2022 | 98 | 21 | 27.27% |
| Dec 31, 2021 | 91 | 14 | 18.18% |
| Sep 30, 2021 | 83 | 6 | 7.79% |
| Jun 30, 2021 | 86 | - | - |
| Mar 31, 2021 | 77 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Acadia Pharmaceuticals | 798 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Relay Therapeutics | 202 |
| Celcuity | 155 |
| Parabilis Medicines | 145 |
TNGX News
- 25 days ago - Tango Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Tango Therapeutics price target raised to $68 from $66 at H.C. Wainwright - TheFly
- 6 weeks ago - Tango Therapeutics price target raised to $35 from $32 at Guggenheim - TheFly
- 7 weeks ago - Tango Therapeutics reports Q2 EPS (37c), consensus (32c) - TheFly
- 7 weeks ago - Tango Therapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Tango Therapeutics Earnings release: Q2 2026 - Filings